Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Cervical Intraepithelial Neoplasia: early-phase trial registry

3 of 7 indexed Cervical Intraepithelial Neoplasia trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 3 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Cervical Intraepithelial Neoplasia: 7 US clinical trials tracked, 3 recruiting.

Cervical Intraepithelial Neoplasia is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Tigris Pharmaceuticals, running 1 of these trials.

Enrollment posture brief

Registry condition cervical-intraepithelial-neoplasia

OPEN 3 | RECR 43% | LATE 1 | EARLY 5 | RANK #2497 | SPON 1

Nearest open-share peer: Adrenoleukodystrophy (43% recruiting · 7 trials)

ACL Tear71.4%ACL57.1%Cervical Intraepithelial (th…43%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Cervical Intraepithelial Neoplasia

Cervical Intraepithelial Neoplasia lists 3 open slots (43% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Cervical Intraepithelial Neoplasia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Cervical Intraepithelial Neoplasia is recruiting below its size-band peers.

    3 of 7 indexed trials (42.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Cervical Intraepithelial Neoplasia trials is spread across many organizations.

    Tigris Pharmaceuticals accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Typical Cervical Intraepithelial Neoplasia enrolment sits around 81 participants.

    Median target enrolment is 81 among the 7 trials that report a genuine target (sentinel values excluded). 4 of those (57.1%) plan for fewer than 100 participants.

  4. Cervical Intraepithelial Neoplasia research is mostly interventional.

    7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 23Phase 41

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3
Phase 4 1

Named interventions

Most-linked intervention names on Cervical Intraepithelial Neoplasia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Candin® Biological
1 trials
PepCan Biological
1 trials
HPV9 Low formulation Biological
1 trials
HPV9 Medium formulation Biological
1 trials
HPV9 High formulation Biological
1 trials
A007 Drug
1 trials
Gardasil 9 Biological
1 trials
CervImage device Device
1 trials

US sites by state

Facility locations filed on Cervical Intraepithelial Neoplasia trials. A trial with sites in several states counts in each.

Louisiana 3 trials
California 3 trials
Nevada 2 trials
Georgia 2 trials
Florida 2 trials
Virginia 1 trials
Ohio 1 trials
New York 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Cervical Intraepithelial Neoplasia page

7 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 3 Cervical Intraepithelial Neoplasia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Tigris Pharmaceuticals sponsors the most Cervical Intraepithelial Neoplasia trials on record, review their full trial history before evaluating a specific study. See Tigris Pharmaceuticals's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cervical Intraepithelial Neoplasia condition card totals 7 registered trials; most-linked intervention Candin®; top US site state Louisiana. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.